---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031680"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:20:37.993402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences enrolls first patient in NANOCLAMP AF study for AF treatment using nPulse system

## Summary
- First procedure completed at St. Helena Hospital in St. Helena, CA with nPulse Cardiac Surgical System using nanosecond PFA.
- NANOCLAMP AF is a single-arm, prospective multicenter study for safety/effectiveness of nPulse in concomitant AF procedures.
- nPulse system granted FDA Breakthrough Device Designation in July 2024 and enrolled in FDA's TAP program.
- Multiple U.S. and two international sites planned; study follows recent FDA IDE approval.

## SEC filing metadata
- accession: 0001437749-25-031680
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925031680/0001437749-25-031680-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925031680/plse20251024_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031680
- JSON: https://secwatch.observer/filing/0001437749-25-031680.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031680.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.